Fig. 3From: Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trialKaplan-Meier curve of the 28-day mortality rate. Kaplan–Meier curve depicting time-to-event analysis of the 28-day mortality rate in patients treated with imatinib and placebo. The unadjusted hazard ratio was calculated by Cox regression analysisBack to article page